Skip to Content

Cronos Group Inc CRON

Morningstar Rating
$2.27 −0.03 (1.30%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Price vs Fair Value

CRON is trading at a 815% premium.
Price
$2.30
Fair Value
$4.80
Uncertainty
Very High
1-Star Price
$4.62
5-Star Price
$3.51
Economic Moat
Rdzrq
Capital Allocation
Vjddkppk

Bulls Say, Bears Say

Bulls

Altria Group’s investment of $1.8 billion provides Cronos with capital and a strategic partner with significant product development, branding, and regulatory experience. If successful, Altria Group may increase its ownership of Cronos or potentially acquire it.

Bears

Cronos' small size adds difficulty to reaching profitability, as it struggles to leverage overhead expenses.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CRON is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$2.30
Day Range
$2.242.33
52-Week Range
$1.643.14
Bid/Ask
$2.25 / $2.30
Market Cap
$867.17 Mil
Volume/Avg
840,867 / 2.6 Mil

Key Statistics

Price/Earnings (Normalized)
1,396.06
Price/Sales
9.30
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Cronos Group, headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the US, the company has an option to acquire 5.9% of US multistate operator PharmaCann on a fully diluted basis upon easing of federal prohibition.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Small Growth
Total Number of Employees
356

Competitors

Valuation

Metric
CRON
CGC
TLRY
Price/Earnings (Normalized)
1,396.06
Price/Book Value
0.811.540.38
Price/Sales
9.302.131.58
Price/Cash Flow
Price/Earnings
CRON
CGC
TLRY

Financial Strength

Metric
CRON
CGC
TLRY
Quick Ratio
26.511.090.96
Current Ratio
28.191.581.92
Interest Coverage
−3.63−4.39
Quick Ratio
CRON
CGC
TLRY

Profitability

Metric
CRON
CGC
TLRY
Return on Assets (Normalized)
−0.28%−17.78%−1.42%
Return on Equity (Normalized)
−0.29%−46.87%−1.82%
Return on Invested Capital (Normalized)
−4.97%−16.41%−0.92%
Return on Assets
CRON
CGC
TLRY
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - Specialty & Generic Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Zoetis Inc Class A
ZTS
QnbbytqbpfTfjtk$79.8 Bil
Merck KGaA ADR
MKKGY
StbcprzxfSslrltw$71.0 Bil
Haleon PLC ADR
HLN
SrxwhzrdYthf$37.5 Bil
Teva Pharmaceutical Industries Ltd ADR
TEVA
MjlygtgzNzk$18.4 Bil
Dr Reddy's Laboratories Ltd ADR
RDY
CwmdbrpzRjhb$12.7 Bil
Viatris Inc
VTRS
GpgmcnhwpBbd$12.4 Bil
Catalent Inc
CTLT
DftfymlkMsqrl$10.2 Bil
Perrigo Co PLC
PRGO
LjxtvrnhQgsv$3.5 Bil
Prestige Consumer Healthcare Inc
PBH
JhnqqzlqyWzwrjs$3.4 Bil
Curaleaf Holdings Inc
CURLF
KgphzdmWnt$2.8 Bil

Sponsor Center